Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.07)
# 3,968
Out of 4,670 analysts
8
Total ratings
20%
Success rate
-50.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $56.06 | -14.38% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $4 → $3 | $0.68 | +341.18% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $71.72 | +8.76% | 1 | Aug 3, 2022 | |
| BNOX Bionomics | Initiates: Outperform | $17 | $0.29 | +5,672.50% | 1 | Jan 10, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $20.20 | +98.02% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $1.90 | +1,110.53% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $56.06
Upside: -14.38%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $4 → $3
Current: $0.68
Upside: +341.18%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $71.72
Upside: +8.76%
Bionomics
Jan 10, 2022
Initiates: Outperform
Price Target: $17
Current: $0.29
Upside: +5,672.50%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $20.20
Upside: +98.02%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $1.90
Upside: +1,110.53%